Scleroderma Market Trends, Size, and Forecast 2024-2033

Overview and Scope

Scleroderma is a rare, chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that forms the structure of the skin and other tissues. The different treatments cure or halt excessive collagen production, effectively manage symptoms, and reduce the risk of complications associated with scleroderma.

Sizing and Forecast

The scleroderma market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to $2.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to advances in diagnosis, immunological research, therapeutic developments, awareness and education, genetic studies.

The scleroderma market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to biological therapies, precision medicine, stem cell therapies, genomic and biomarker research, global collaborations. Major trends in the forecast period include digital health solutions, focus on microbiome, patient-centric care, regenerative medicine, health equity and access.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

Segmentation & Regional Insights

The scleroderma market covered in this report is segmented –

1) By Treatment: Medication, Surgery, Other Treatments
2) By Indication: Systemic Scleroderma, Localized Scleroderma
3) By End User: Hospital, Pharmaceutical Stores, Other End Users

North America was the largest region in the scleroderma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12615&type=smp

Major Driver Impacting Market Growth

The greater prevalence of scleroderma is driving the scleroderma market going forward. Scleroderma is a chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that forms the structure of skin and other tissues. An unregulated immune response, possibly triggered by various environmental factors, leads to the development of this condition. As the number of cases rises, the importance of improved diagnosis and treatment becomes evident. Scleroderma therapeutics are crucial to managing illness and alleviating symptoms by regulating the immune response and mitigating exposure to environmental risk factors. For instance, in June 2022, according to Karger Publishers, a Switzerland-based publisher of peer-reviewed journals, 19,000 people had scleroderma in the UK and 2.5 million people worldwide. Furthermore, in July 2021, a research article published by Oxford Academic Press, a university press affiliated with the University of Oxford in the UK, revealed that the global prevalence of scleroderma was 17.6 cases per 100,000 people and the incidence rate was 1.4 cases per 100,000 person-years. As a result, the greater prevalence of scleroderma is driving the scleroderma market.

Key Industry Players

Major companies operating in the scleroderma market report are Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., Celgene Corporation, Actelion Pharmaceuticals Inc., H.A.C. Pharma

The scleroderma market report table of contents includes:

1. Executive Summary

2. Scleroderma Market Characteristics

3. Scleroderma Market Trends And Strategies

4. Scleroderma Market – Macro Economic Scenario

5. Global Scleroderma Market Size and Growth

…

32. Global Scleroderma Market Competitive Benchmarking

33. Global Scleroderma Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Scleroderma Market

35. Scleroderma Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model